GBA1 and Parkinson disease: Virally mediated gene inhibition (RNAi) or editing (CRISPR-Cas9) are two options here [135], but where PD is seen in the context of GBA1 mutations, expression of the normally functioning wild-type gene may prove beneficial [136].